Synovis Life Technologies, Inc.
Synovis Life Technologies, Inc. (Nasdaq: SYNO)
St. Paul, MN 55114
http://www.synovislife.com/
52-week low / high: $7.10 / $24.61
Shares Outstanding: 12.29 million
Market Capitalization: $299.33 million
Synovis Life Technologies operates two distinct medical business units—surgical and interventional—for the treatment of disease.
The surgical unit is comprised of implantable biomaterial products and devices for microsurgery and surgical tools. The interventional business unit develops prototypes and manufactures coils, helices, stylets, guidewires, and other complex micro wire, polymer and micro-machined metal components used in minimally invasive devices for cardiac rhythm management (CRM), neurostimulation, vascular and other procedures.
The interventional business unit also develops technology platforms, which can be adapted for the company's customers. The interventional business unit generated 74% of the company’s revenues in fiscal 2006.
Synovis’ fiscal third quarter 2007 revenues were up 39% to $18.2 million versus $13.1 million in the same quarter 2006. Sequentially, revenues were up 10% from the second fiscal quarter. Net income was $1.2 million for the July quarter, $0.10 per diluted share versus a loss of $526,000 in the year before period. Analysts are projecting revenues of $67 million for the year, 20% ahead of 2006 revenues. 2007 EPS is expected to be $0.27 per diluted share versus a $0.12 loss in 2006. The company is in a strong cash position, with $49.8 million in cash, equivalents and short-term investments as of July 31, 2007. The company generated $4.1 million cash from operations in the third quarter.
St. Paul, MN 55114
http://www.synovislife.com/
52-week low / high: $7.10 / $24.61
Shares Outstanding: 12.29 million
Market Capitalization: $299.33 million
Synovis Life Technologies operates two distinct medical business units—surgical and interventional—for the treatment of disease.
The surgical unit is comprised of implantable biomaterial products and devices for microsurgery and surgical tools. The interventional business unit develops prototypes and manufactures coils, helices, stylets, guidewires, and other complex micro wire, polymer and micro-machined metal components used in minimally invasive devices for cardiac rhythm management (CRM), neurostimulation, vascular and other procedures.
The interventional business unit also develops technology platforms, which can be adapted for the company's customers. The interventional business unit generated 74% of the company’s revenues in fiscal 2006.
Synovis’ fiscal third quarter 2007 revenues were up 39% to $18.2 million versus $13.1 million in the same quarter 2006. Sequentially, revenues were up 10% from the second fiscal quarter. Net income was $1.2 million for the July quarter, $0.10 per diluted share versus a loss of $526,000 in the year before period. Analysts are projecting revenues of $67 million for the year, 20% ahead of 2006 revenues. 2007 EPS is expected to be $0.27 per diluted share versus a $0.12 loss in 2006. The company is in a strong cash position, with $49.8 million in cash, equivalents and short-term investments as of July 31, 2007. The company generated $4.1 million cash from operations in the third quarter.
For access to the full article, you must be a registered member - it's FREE.
Already a member? Please log in below
Not Registered?
Register today and enjoy all that SmallCapInvestor.com has to offer, including:
- Daily small cap stock profiles.
- Intra-day coverage of Russell 2000 companies.
- Research and insights from our analysts.
- Special reports.
